Johnson & Johnson
(XSWX:JNJ)
CHF
205.1
-3.8 (-1.82%)
Market Cap: 494.51 Bil
Enterprise Value: 521.16 Bil
PE Ratio: 29.35
PB Ratio: 7.52
GF Score: 76/100 Johnson & Johnson at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022 / 03:10PM GMT
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Great. Well, thanks for joining us, everybody. I'm Terence Flynn, the U.S. pharma analyst at Morgan Stanley. We're very pleased to have Johnson & Johnson with us today. Just quickly before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Today from the company, we have Joaquin Duato, the company's CEO; and Joe Wolk, Executive Vice President and CFO. Thank you both so much for being here. Great to see you in person.
Joseph J. Wolk
Johnson & Johnson - Executive VP & CFO
Nice to see you, Terence.
Joaquin Duato
Johnson & Johnson - CEO & Director
Thank you. Thanks for having us.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot